Biotech | March 23, 2022
Orgenics to conduct toxicology study on its intransal COVID-19 vaccine candidate
Data to establish the safety profile and human dose of vaccine candidate
Data to establish the safety profile and human dose of vaccine candidate
The first-of-its-kind unique centre will increase access to preventive & primary care
The scope of supply includes the skid-mounted plant as well as on-site installation and commissioning support
The expansion makes Exothera one of the largest viral vector facilities in Europe
Saransh Chaudhary, President, Global Critical Care Division, Venus Remedies and CEO, Venus Medicine Research Centre In conversation with Thomas C Thottathil, Editor, www.indianpharmapost.com identified key areas that the company is focusing on in its Mission 2025
New data, including two late-breaking clinical trial presentations on mavacamten and a new analysis of the GUARD-AF study, reinforce the company’s continued commitment to those living with cardiovascular disease
Hester's initial pet care portfolio will include products ranging from dermatology, grooming, anti-infective, and speciality products
Expanded capabilities across pharma services network accelerate innovation and enhance productivity for customers
Divsa's coverage across Central America bridges Barentz' leading positions in North and South America
Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships
Subscribe To Our Newsletter & Stay Updated
